AR024476A1 - Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. - Google Patents
Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen.Info
- Publication number
- AR024476A1 AR024476A1 ARP000103183A ARP000103183A AR024476A1 AR 024476 A1 AR024476 A1 AR 024476A1 AR P000103183 A ARP000103183 A AR P000103183A AR P000103183 A ARP000103183 A AR P000103183A AR 024476 A1 AR024476 A1 AR 024476A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- treatment
- benzacepin
- acetic acid
- acid derivatives
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000013875 Heart injury Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 238000009098 adjuvant therapy Methods 0.000 abstract 2
- 231100001012 cardiac lesion Toxicity 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 231100000457 cardiotoxic Toxicity 0.000 abstract 1
- 230000001451 cardiotoxic effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de derivados de ácidos benzacepin-N-acético, que en posicion alfa con relacion al átomo de nitrogeno contienen un grupo oxo y en posicion 3 estánsustituidos con un radical 1-(carboxialquil)-ciclopentil-carbonil-amino, y sus sales y ésteres biolábiles, para la profilaxis y/o tratamiento de lesionescardíacas causadas por dosis cardiotoxicas de fármacos o productos químicos, en mamíferos superiores y particularmente seres humanos. En particular,comprende la profilaxis y/o tratamiento de lesiones cardíacas, particularmente del miocardio, que pueden producirse en el marco de una quimioterapiacitostática. Además se describe el uso de dichos derivados de ácido benzacepin-N-acético para el tratamiento adyuvante en el marco de terapias en que seutilizan medicamentos con efectos secundarios oxidativo-toxicos. También se describe la preparacion de medicamentos adecuados para esta profilaxis y/otratamiento adyuvante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19932555A DE19932555A1 (de) | 1999-07-13 | 1999-07-13 | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024476A1 true AR024476A1 (es) | 2002-10-02 |
Family
ID=7914519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103183A AR024476A1 (es) | 1999-07-13 | 2000-06-23 | Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6906059B2 (es) |
| EP (1) | EP1200095B1 (es) |
| JP (1) | JP4824235B2 (es) |
| KR (1) | KR100738940B1 (es) |
| CN (1) | CN1267099C (es) |
| AR (1) | AR024476A1 (es) |
| AT (1) | ATE306926T1 (es) |
| AU (1) | AU782733B2 (es) |
| BR (1) | BR0012442A (es) |
| CA (1) | CA2377904C (es) |
| CZ (1) | CZ299070B6 (es) |
| DE (2) | DE19932555A1 (es) |
| DK (1) | DK1200095T3 (es) |
| ES (1) | ES2246874T3 (es) |
| HK (1) | HK1049116B (es) |
| HU (1) | HUP0202424A3 (es) |
| IL (2) | IL147604A0 (es) |
| MX (1) | MXPA02000411A (es) |
| NO (1) | NO329558B1 (es) |
| NZ (1) | NZ517130A (es) |
| PL (1) | PL198723B1 (es) |
| RU (1) | RU2268727C2 (es) |
| SK (1) | SK286020B6 (es) |
| TR (1) | TR200200053T2 (es) |
| TW (1) | TWI280880B (es) |
| UA (1) | UA73134C2 (es) |
| WO (1) | WO2001003699A1 (es) |
| ZA (1) | ZA200200265B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| CA2447598A1 (en) * | 2001-05-18 | 2002-11-28 | Solvay Pharmaceuticals Gmbh | Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments |
| JP4521185B2 (ja) * | 2001-09-10 | 2010-08-11 | テイボテク・フアーマシユーチカルズ・リミテツド | ヘキサヒドロ−フロ［２，３−ｂ］フラン−３−オールの製造法 |
| IL162645A0 (en) | 2002-01-16 | 2005-11-20 | Solvay Pharm Bv | solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds |
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| PL1687006T3 (pl) | 2003-11-18 | 2008-01-31 | Solvay Pharm Gmbh | Kompozycje farmaceutyczne do leczenia zaburzeń czynności nerek |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| JP2008524159A (ja) | 2004-12-15 | 2008-07-10 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＮＥＰ阻害剤、内因性エンドセリン産生系の阻害剤およびＨＭＧＣｏＡレダクターゼ阻害剤を含有する医薬組成物 |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| US8709738B2 (en) * | 2006-02-27 | 2014-04-29 | Quintiles Transnational Corporation | Methods for predicting cardiac toxicity |
| WO2007102171A2 (en) * | 2006-03-07 | 2007-09-13 | Panacea Biotec Ltd | Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition |
| US20070292503A1 (en) * | 2006-06-16 | 2007-12-20 | Gorissen Henricus R | Oral pharmaceutical composition of poorly water-soluble active substance |
| US20070299054A1 (en) * | 2006-06-22 | 2007-12-27 | Rajesh Jain | Oral pharmaceutical composition of a poorly water-soluble active agent |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2850078A1 (de) * | 1978-11-18 | 1980-05-29 | Basf Ag | Aminopropanolderivate des 6-hydroxy-2,3,4,5-tetrahydro-1h-1- benzazepin-2-ons |
| WO1995003305A1 (en) * | 1993-07-21 | 1995-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Fused benzazepine derivative and pharmaceutical composition containing the same |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| ATE233104T1 (de) * | 1997-09-18 | 2003-03-15 | Janssen Pharmaceutica Nv | Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
-
1999
- 1999-07-13 DE DE19932555A patent/DE19932555A1/de not_active Withdrawn
-
2000
- 2000-06-23 AR ARP000103183A patent/AR024476A1/es unknown
- 2000-07-05 TW TW089113263A patent/TWI280880B/zh active
- 2000-07-10 HK HK03101159.2A patent/HK1049116B/zh not_active IP Right Cessation
- 2000-07-10 NZ NZ517130A patent/NZ517130A/en not_active IP Right Cessation
- 2000-07-10 CA CA002377904A patent/CA2377904C/en not_active Expired - Fee Related
- 2000-07-10 DK DK00947960T patent/DK1200095T3/da active
- 2000-07-10 JP JP2001508979A patent/JP4824235B2/ja not_active Expired - Fee Related
- 2000-07-10 RU RU2002102709/15A patent/RU2268727C2/ru not_active IP Right Cessation
- 2000-07-10 TR TR2002/00053T patent/TR200200053T2/xx unknown
- 2000-07-10 SK SK14-2002A patent/SK286020B6/sk not_active IP Right Cessation
- 2000-07-10 IL IL14760400A patent/IL147604A0/xx active IP Right Grant
- 2000-07-10 KR KR1020027000361A patent/KR100738940B1/ko not_active Expired - Fee Related
- 2000-07-10 HU HU0202424A patent/HUP0202424A3/hu not_active Application Discontinuation
- 2000-07-10 ES ES00947960T patent/ES2246874T3/es not_active Expired - Lifetime
- 2000-07-10 WO PCT/EP2000/006525 patent/WO2001003699A1/de not_active Ceased
- 2000-07-10 BR BR0012442-7A patent/BR0012442A/pt not_active Application Discontinuation
- 2000-07-10 AU AU61572/00A patent/AU782733B2/en not_active Ceased
- 2000-07-10 MX MXPA02000411A patent/MXPA02000411A/es active IP Right Grant
- 2000-07-10 DE DE50011388T patent/DE50011388D1/de not_active Expired - Lifetime
- 2000-07-10 CZ CZ20020052A patent/CZ299070B6/cs not_active IP Right Cessation
- 2000-07-10 CN CNB008102015A patent/CN1267099C/zh not_active Expired - Fee Related
- 2000-07-10 EP EP00947960A patent/EP1200095B1/de not_active Expired - Lifetime
- 2000-07-10 PL PL353012A patent/PL198723B1/pl not_active IP Right Cessation
- 2000-07-10 AT AT00947960T patent/ATE306926T1/de active
- 2000-10-07 UA UA2002021058A patent/UA73134C2/uk unknown
-
2002
- 2002-01-11 NO NO20020132A patent/NO329558B1/no not_active IP Right Cessation
- 2002-01-11 ZA ZA200200265A patent/ZA200200265B/xx unknown
- 2002-01-13 IL IL147604A patent/IL147604A/en not_active IP Right Cessation
- 2002-01-14 US US10/043,268 patent/US6906059B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024476A1 (es) | Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. | |
| AR008878A1 (es) | Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento. | |
| UY38880A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| ES2054860T5 (es) | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. | |
| AR024441A1 (es) | Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento. | |
| AR007640A1 (es) | DERIVADOS DE FENILALANINA, PROCEDIMIENTO PARA PREPARARLOS, PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN Y EMPLEO DE LOS MISMOS PARA PREPARAR UNMEDICAMENTO QUE ACTUA COMO INHIBIDOR DE LA INTEGRINA ALFA(v) | |
| ES2152222T3 (es) | Sulfonamidas, su preparacion y su uso como medicamento e intermedio. | |
| AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
| ES2115725T3 (es) | Hidrocloruro de triazoliltiometiltiocefalosporina, su hidrato cristalino y la preparacion de este. | |
| AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| AR004108A1 (es) | Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas | |
| AR010894A1 (es) | Aminoacidos aromaticos biciclicos, un procedimiento para prepararlos, preparaciones farmaceuticas que lo contienen y el empleo de los mismos parapreparar un medicamento que actua como inhibidor de la integrina. | |
| AR024440A1 (es) | AGONISTAS DEL RECEPTOR A2A DE ETER PROPARGIL FENILICO, COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA PREPARAR UN MEDICAMENTO. | |
| AR039633A2 (es) | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
| ES2045182T3 (es) | Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen. | |
| UY26371A1 (es) | Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen | |
| AR013864A1 (es) | COMPOSICIONES FARMACEUTICAS PARA LA PREVENCIoN PRIMARIA DEL CANCER DE PECHO EN UNA MUJER POST MENOPÁUSICA Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO | |
| ES2123499T3 (es) | Metodos y composiciones para tratamiento de infecciones virales. | |
| ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. | |
| MX9300558A (es) | Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene. | |
| AR002957A1 (es) | Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen. | |
| ES2182504T3 (es) | Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. | |
| ES2056947T3 (es) | Productos opticamente activos de derivados de 20,21-dinoreburnamenina, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. | |
| ES2177103T3 (es) | Terapia de combinacion para el tratamiento del sida. | |
| PE20050307A1 (es) | 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metoxipiridin-3-il)propil]benzamida, su uso como un medicamento y preparaciones farmaceuticas que lo comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |